Finally, we prepared an animal model of breast cancer, and verified the anti-tumor therapeutic effect, safety evaluation and biologic mechanisms of TROP-2 CAR-T combined with CBP in vivo.<h4>Results</h4>Bioinformatics analysis and in vitro experiments showed that TROP-2 was widely expressed in breast cancer cells. Here, TACSTD2 is linked to breast carcinoma.